Xconomy Forum to Convene Leaders of Dendreon, Seattle Genetics
Summary
Dendreon (NASDAQ: DNDN) has now introduced the first FDA-approved treatment that fights cancer by actively stimulating the immune system—and been rewarded with a $5.7 billion market valuation at yesterday’s close.Seattle Genetics (NASDAQ: SGEN) has released remarkable clinical trial data in the past few weeks suggesting it has created a potent new drug for Hodgkin’s disease, and what could be the first commercially successful “empowered antibody” for cancer.Given the historic nature of what’s been happening here in Seattle lately, I’m thrilled to announce today that we at Xconomy are convening the leaders of these companies to talk about how to make sure the Northwest doesn’t let this new momentum slip away.The CEOs of Dendreon, Seattle Genetics, and two of the most promising private biotechs in the Northwest—Alder Biopharmaceuticals and Calistoga Pharmaceuticals—are all coming together for a lively panel discussion the evening of November 29 at PATH’s new headquarters in South Lake Union.I hope to draw out their individual and collective wisdom on how Seattle can sustain its renewed success and continue making a global impact on the life sciences industry over the coming decades.